patients," 2 respectively. The passage of time allows one to place such advances in perspective.5' Media publicity was not necessary for the development of and advances in valve replacement or for many other great advances in medicine. Moreover, the publicity may interfere with the patient's and the family's right to privacy, even if they give "informed consent"; there must be some concern about the ability of a patient with severe end-stage chronic heart disease and serious disability to make informed balanced decisions about such matters. Since publicity may have more disadvantages than benefits, more restraint on the part of investigators is needed.
In the 1950s Starr felt he would have no chance of obtaining research funds from national agencies and organizations because he was young and without a track-record and because the feasibility of his proposed techniques being successful was unproven.9' * Therefore, he turned to the Oregon Affiliate of the American Heart Association for funding of his initial research. Along with the problems Starr encountered in obtaining research funds, which are still present today, there are several additional current problems encountered by physicians'0 in obtaining funds from national agencies and organizations, including the following: (1) Patient research is usually not as pure and precise as animal or bench research and thus in the review process fares less well. (2) In the review process, funding sources employ scientists who are not experienced to judge patient research. Moreover, some of these scientists are in principle opposed to patient research. All of these factors are a special problem for the cardiac clinical investigator (a member of that subset of physician-clinicians whose laboratory is the patient's bedside, the diagnostic laboratories, and the operating room). These individuals are increasingly involved in industry-initiated research, and impact of this reliance is of major concern. They have been considered an "endangered spe-*Starr A: Personal communication. RAHIMTOOLA cies, 1 12 and their ranks are being seriously denuded.
Rescue attempts have been initiated, for example, the new investigator and the clinician-scientist awards, etc. Some of these awards are a two-edged sword; for example, although special consideration is given in the review process to the new investigator, there are no dedicated funds for the new investigator award, and therefore these young physicians compete with other investigators and having done so successfully they can get only limited funds. Funds could be dedicated for the new investigator award, and the ceiling for each award could be increased. Moreover, what if these efforts eventually prove to be insufficient? The issue is so important that everything possible must be done now. Therefore, the National Institutes of Health should also give serious consideration to creating a separate Cardiovascular Clinical Investigation Study Section in which clinical investigator-initiated research grant applications would be judged by clinical investigators with experience in these and related areas of research; the American Heart Association, which has already started on a similar course, should consolidate and extend its program.
The 1960s saw the emergence of Human Research Committees, and the 1970s saw the passage of the law on cardiovascular devices. '1 Both were needed. These committees and the Food and Drug Administration are playing an increasing role in cardiovascular research and in health care. If a radical new procedure, such as valve replacement, was proposed today, what would be likely to occur? First, a committee of expert scientists and ethicists might be set up to evaluate whether we were ready for such a procedure and to consider if this was the right direction to pursue. Committees as a rule are a poor mechanism for the introduction of original or innovative thoughts and approaches; the innovative individual investigator is superior in this regard and his/her rights must be aggressively protected. Second, limited approval might be given for such a "lifethreatening" innovative procedure, and the investigator might be required to report after each "experiment" and obtain further approval. A nonfunctioning prosthetic aortic or mitral valve is as "lifethreatening" as a nonfunctioning transplanted heart or a totally mechanical heart. Starr performed the first eight mitral valve replacements in 6 months. By comparison, the long delay after implantation of the first totally mechanical heart to the second such procedure is apparent; is this an additional price for the "hoopla" that was associated with the first procedure? Recall that Starr's first patient died within 24 hours and four of Harken's first five patients died; the limitations and 2 strengths of conclusions that are drawn from the first or first few procedures must be kept in mind. Investigators must be allowed to study an adequate number of patients and not be restricted by too many controls; however, investigators must recognize the benefits of having their results judged by proper review of published results in the scientific literature rather than by the media. Third, the smallest changes in prostheses now appear to require unequivocal proof of lack of significant change in prosthesis and/or in safety and efficacy before they can be used clinically. The 1980s are not the same as the 1960s; one reason for the difference is that we now have prosthetic valves with long-term proven track-records. Nevertheless, if we always demand absolute proof of safety and efficacy and make the process of change very difficult, we might ensure that new and innovative devices will only be tested and proven overseas; therefore, it seems reasonable that restraints should be applied in balance. Finally, it is highly likely that if valve replacement was introduced today there would be demands for prospective, randomized, clinical trials to prove the superiority of valve replacement over medical therapy. It is likely that other issues (such as the fact that adequate or maximal medical therapy cannot be properly defined, that the beneficial effects of medical therapy on survival of patients with severe valve disease are unproven, and that large prospective randomized clinical trials have a multitude of problems) may be ignored. As one reflects on the last 25 years, one has to consider the probability that if randomized clinical trials of valve replacement had been completed during the first 20 years, they might have hindered the development of valve surgery as a major resource in the management of patients with valvular heart disease. If these perceptions are correct, then a midcourse correction of these excesses is needed.
In conclusion, on the twenty-fifth anniversary of valve replacement, we can be proud of the achievements of medicine and of investigators. However, we must correct problems that deter or slow such advances. These include excessive premature publicity, difficulties experienced by clinical and young investigators in trying to obtain funding, inappropriate clinical trials, and an imbalance between patient protection and innovation.
